Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
The present invention relates to novel compounds that can be used as antiinflammatory, immunomodulatory and antiproliferatory agents. In particular the invention refers to new compounds which inhibit dihydroorotate dehydrogenase (DHODH), a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of diseases, in particular their use in diseases where there is an advantage in inhibiting dihydroorotate dehydrogenase (DHODH).
1. A compound of the general formula (1) and salts thereof,
wherein
A, X is cyclopentene ring, wherein one or more of the carbon atoms of the ring can carry a substituent R 1 ;
D is O, S, SO 2 , NR 4 , or CH 2 ;
Z 1 and Z are O;
R 1 is independently H, halogen, haloalkyl, haloalkyloxy or alkyl;
R 2 is OR 6 ;
R 3 is H, alkyl, cycloalkyl, aryl, arylalkyl, alkoxy, O-aryl, O-cycloalkyl, halogen, aminoalkyl, alkylamino, hydroxylamino, hydroxylalkyl, haloalkyl, haloalkyloxy, heteroaryl, alkylthio, S-aryl, or S-cycloalkyl;
R 4 is H, alkyl, cycloalkyl, aryl, or heteroaryl;
R 5 is H, OH, alkoxy, O-aryl, alkyl, or aryl;
R 6 is H, alkyl, cycloalkyl, aryl, heteroaryl, arylalkyl, alkylaryl, alkoxyalkyl, acylmethyl, (acyloxy)alkyl, non-symmetrical (acyloxy)alkyldiester, or dialkylphosphate;
R 7 is H, alkyl, aryl, alkoxy, O-aryl, cycloalkyl, or O-cycloalkyl;
R 8 is hydrogen or alkyl;
E is a substituted or unsubstituted phenyl, naphthyl, anthracenyl, or cycloalkyl;
Y is cycloalkyl or a monocyclic or polycyclic substituted or unsubstituted ring system which contains at least one aromatic ring,
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
r is 0 or 1; and
q is 0 to 10;
with the proviso that when R 2 =OH, and r=1, the following compounds are excluded:
q=0; Y=hydrogen; E=phenylene or naphthylene, phenylene substituted with one or two chlorine atoms or with 2-methyl, 4-methyl, 4-methoxy, 2-ethoxy, 2,6-diethyl, 2-chloro-4-methyl, 4-bromo, 4-cyano, 2,3-difluoro, 2,6-difluoro, 2,3,4-trifluoro;
q=0; Y=phenyl; E=phenylene;
q=1; m=1; n=1; R 3 =H; E=phenylene; Y=4-chloro-phenyl; D=O, S;
q=1; m=1; n=1; R 3 =H; E=phenylene; Y=4-phenyl; D=O.
2. The compound of claim 1 , wherein r=1.
3. The compound of claim 1 , wherein r=1, and E is phenyl, 1-naphthyl, 2-naphthyl, 2-naphthyl, 1-anthracenyl, 2-anthracenyl, or cycloalkyl.
4. The compound of claim 1 , wherein each alkyl group is a linear branched chain having 1 to 6 carbon atoms.
5. The compound of claim 1 , wherein each alkyl group is unsubstituted or substituted by one or more substitutents.
6. The compound of claim 5 , wherein said one or more substitutents are selected from the group consisting of —CO 2 R″, —CONHR″, —CR″O, —SO 2 NR″, —NR″—CO-haloalkyl, —NO 2 , —NR″—SO 2 -haloalkyl, —NR″—SO 2 -alkyl, —SO 2 -alkyl, —NR″—CO-alkyl, —CN, alkyl, cycloalkyl, aminoalkyl, alkylamino, alkoxy, —OH, —SH, alkylthio, hydroxyalkyl, hydroxyalkylamino, halogen, haloalkyl, haloalkyloxy, aryl, arylalkyl or heteroaryl,
wherein R″ is independently hydrogen, haloalkyl, hydroxyalkyl, alkyl, cycloalkyl, aryl, heteroaryl or aminoalkyl.
7. The compound of claim 1 , wherein each cycloalkyl group is a non-aromatic ring system containing 3 to 8 carbon atoms.
8. The compound of claim 1 , wherein each heteroaryl group is a 5- or 6-membered heterocyclic ring which contains at least one heteroatom.
9. The compound of claim 8 , wherein said at least one heteroatom is selected from the group consisting of O, N, and S.
10. The compound of claim 8 , wherein each heteroaryl group is independently selected from the group consisting of oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, thiazol-2-yl, thiazol-4-yl, thiazol-5-yl, isothiazol-3-yl, isothiazol-4-yl, isothiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,4-oxadiazol-5-yl, 1,2,4-thiadiazol-3-yl, 1,2,4-thiadiazol-5-yl, 1,2,4-oxadiazol-3-yl, 1,2,5-oxadiazol-4-yl, 1,2,5-thiadiazol-3-yl, 1-imidazolyl, 2-imidazolyl, 1,2,5-thiadiazol-4-yl, 4-imidazolyl, 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-furanyl, 3-furanyl, 2-thienyl, 3-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimindinyl, 3-pyridazinyl, 4-pyridazinyl, 2-pyrazinyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, indolyl, indolinyl, benzo-[b]-furanyl, benzo[b]thiophenyl, benzimidazolyl, benzothiazolyl, quinazolinyl, quinoxazolinyl, or preferably isoxazol-3-yl, isoxazol-4-yl, isoxazol-5-yl, quinolinyl, tetrahydroquinolinyl, isoquinolinyl, tetrahydroisoquinolinyl group.
11. The compound of claim 1 , which is in the form of a salt.
12. A pharmaceutical composition comprising a compound as defined in claim 1 in combination with a pharmaceutically acceptable diluent or carrier.
13. A method of making the pharmaceutical composition of claim 12 , comprising combining the compound with the pharmaceutically acceptable diluent or carrier.
14. A method of inhibiting dihydrooratate dehydrogenase for treating at least one disease selected from the group consisting of rheumatism, diseases that are caused by protozoal infestations in humans and animals, diseases that are caused by viral infections and Pneumocystis carinii, fibrosis, uveitis, rhinitis, asthma, athropathy, sepsis, septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, stroke, reperfusion injury, CNS injury, allergy, graft versus host reactions, host versus graft reactions, alzheimer's disease, pyresis, restenosis, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption disease, rheumatoid spondylitis, osteoarthritis, gouty arthritis, multiple sclerosis, insulin dependent diabetes mellitus, non-insulin dependent diabetes, lupus erythematoidis, ulcerative colitis, Morbus Crohn, inflammatory bowel disease, chronic inflammations, and chronic diarrhea in a subject, comprising administering an effective amount of the compound as defined in claim 1 to the subject.
15. The method of claim 14 , wherein the disease is selected from the group consisting of rheumatism, diseases that are caused by protozoal infestations in humans and animals, diseases that are caused by viral infections and Pneumocystis carinii, fibrosis, uveitis, rhinitis, asthma, and athropathy, comprising administering an effective amount of the compound of claim 1 to a subject.
16. A method of treating at least one condition selected from the group consisting of septic shock, endotoxic shock, Gram-negative sepsis, toxic shock syndrome, acute respiratory distress syndrome, stroke, reperfusion injury, CN injury, allergy, graft versus host and host versus graft reactions, alzheimer's, pyresis, restenosis, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcosis, bone resorption disease, multiple sclerosis, insulin dependent diabetes mellitus and non-insulin dependent diabetes, and lupus erythematoidis, ulcerative colitis, Morbus Crohn, inflammatory bowel disease, chronic diarrhea, psoriasis and progressive retinal atrophy, comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.
17. The compound of claim 1 , wherein Y is a cycloalkyl group.
18. The compound of claim 1 , wherein Y is monocyclic or polycyclic substituted or unsubstituted ring system which contains at least one aromatic ring.
19. The compound of claim 1 , wherein Y is a phenyl group.
20. The compound of claim 19 , wherein said phenyl group is unsubstituted.
21. The compound of claim 19 , wherein said phenyl group is substituted.
22. The compound of claim 1 , which is 2-(3-fluoro-3′-methoxy-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid.
23. The compound of claim 1 , which is 2-(3,5-difluoro-2′-methoxy-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid.
24. The compound of claim 1 , which is 2-(2,3,5,6-tetrafluoro-2′-methoxy-biphenyl-4-ylcarbamoyl)-cyclopent-1-enecarboxylic acid.